Two Biotechs Raise Combined $556M in Latest IPOs
Hemab Therapeutics and Seaport Therapeutics raised a combined $556.4 million through their initial public offerings, exceeding expectations to fund late-stage drug development. Hemab priced its offering at $18 per share for nearly 17 million shares, while Seaport sold over 14 million shares at the same price.
Topics: biotech clinical trials funding IPO stock market